Cardiometabolic risk effects of weight‐loss medications: An updated network meta‐analysis
Authors' conclusion
This study found that six FDA-approved weight-loss drugs had a moderately beneficial effect on the cardiometabolic risk profile. In general, tirzepatide was more effective than other pharmacological agents in improving cardiometabolic risk factors.
Study context
- Population
- Obese adults
- Participants
- 24,792 adults31 trials
- Comparison
- Six Food and Drug Administration (FDA)-approved weight-loss medications vs placebo or each other
- Outcome
- Cardiometabolic risk factors
- Follow-up
- ≥1 year
Methodological detailspairwise and network meta-analyses, GRADE quality assessment
- Pairwise and network meta-analyses
- GRADE quality assessment
Pooled result
As reported in the abstract
Reduction in fasting glucose
11.12 mg/dL
95% CI −13.70 to −8.53
Weight-loss drugs
Reduction in HbA1c
0.60 %
95% CI −0.75 to −0.45
Weight-loss drugs
Reduction in waist circumference
5.28 cm
95% CI −6.57 to −4.00
Weight-loss drugs
Original publication
Cardiometabolic risk effects of weight‐loss medications: An updated network meta‐analysis. Diabetes Obes Metab. Published 2 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →